Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.
Papanicolaou S, Kontodimas S, Syriopoulou E, Tsolia M, Theodoridou M, Kremastinou J, Tzanakaki G, Strutton D, Hwang S, Earnshaw SR. Clinical and economic benefits of national immunization with the 13-valent compared to 7- and 10-valent pneumococcal conjugate vaccines in Greece. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A423-4.
Farkouh R, Wilson M, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with other first-line treatment options for early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A369.
Knoll S, Jochum D, Talbird SE. Cost-utility analysis of pneumococcal conjugate vaccines in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A429.
Ismaila A, Pereira J, Robson R, Talbird SE, Standaert B, Rawson N. Budget-impact analysis of adding the new 10-valent pneumococcal conjugate vaccination (PHiD-CV) to routine infant vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A418.
Whillans F, Kwan H, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent and 10-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A425.
Gonzalez-Rojas N, Vieta A, Monreal M, Wolowacz SE. Economic analysis of dabigatran etexilate for the primary prevention of venous thromboembolism following total hip or knee replacement in Spain. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 24, 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A440.
Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.
Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.
Soorapanth S, Brogan AJ, Mrus J, Smets E. Comparative cost-efficacy analysis of darunavir/r for first-line treatment of HIV infection in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 2009. [abstract] Value Health. 12(3):A112.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty with moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Mauskopf J, Schmitt C, Boye KS, McCollam PL, Juniper MD, Birt JA. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 2009 May; 12(2):A148.
Farkouh RA, Wilson MR, Tarrants M, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline versus ropinirole extended release in delaying levodopa in the treatment of early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 2009 May; 12(3):A192.
Mateus C, Wolowacz S, Pereira JA. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in total hip and knee replacement in Portugal. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A148.
Brogan AJ, Soorapanth S, Donatz V, Hill A, Smets E. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. Paris, France. [abstract] Value Health. 2009; 12(7):A426.
Mitra D, Candrilli SD. Inpatient costs and outcomes associated with hepatitis c, human immunodeficiency virus, and co-infection with both in the United States. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 8, 2008. [abstract] Value Health. 2008 Nov; 11(6):A440-1.
Mitra D, Davis KL, Medjedovic J, Beam C, Rustgi V. The economic burden of hcv and hbv co-infection: evidence from United States managed care data. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A440.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Variation in direct medical costs by disease severity among persons with chronic hepatitis c virus. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A335-6.
Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson P, Plumb J. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in patients undergoing total hip or total knee replacement surgery. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A404.
Candrilli SD, Davis KL, Balkrishnan R. Inpatient length of stay and total costs of illnesses of pressing concern for Asian-American and Pacific Islander women in the United States. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A424. Previously presented at the 3rd Annual Asia-Pacific Conference of the International Society for Pharmacoeconomics and Outcomes Research.
Candrilli SD, Davis KL, Balkrishnan R. Inpatient length of stay and total costs of illnesses of pressing concern for Asian-American and Pacific Islander women in the United States. Poster presented at the 2008 ISPOR 3rd Annual Asia-Pacific Conference; September 2008. [abstract] Value Health. 2008 Nov; 11(6):A424.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AR. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008 Jul 1;11(4):563-74.
Candrilli S, Balkrishnan R, O'Brien SH. The effect of injury severity on the incidence and resource utilization-related outcomes of deep vein thrombosis among pediatric trauma admissions in the United States. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A246-7.
Mitra D, Davis KL, Kotapati S, Iloeje U. Real-world treatment patterns in high-risk and metastatic melanoma: evidence from the SEER-medicare linked database. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A83.
Mitra D, Davis KL, Medjedovic J, Beam C, Rustgi VK. Health care utilization and costs associated with chronic hepatitis c in a managed care population. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A103.
Mitra D, Candrilli S, Davis KL, Bapat B. Inpatient costs and outcomes associated with chronic hepatitis c-related complications in the United States. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A107.
Davis KL, Mitra D, Kotapati S. Direct economic burden of high-risk and metastatic melanoma: evidence from the SEER-medicare linked database. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A69-70.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi VK. Direct economic burden of chronic hepatitis c virus in a large managed care population. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A87.
Graham CN, Earnshaw SR, Raymond V. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis in Canada. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A98.
Kotapati S, Mitra D, Davis KL, Iloeje U. Predictors of treatment choice in high-risk and metastatic melanoma: evidence from linked electronic medical records and administrative claims data. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A82-3.
Brennan VK, Wolowacz SE. A systematic review of breast cancer utility weights. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A77.
Pearson IV, Johnson KI. A cost minimization analysis of epoetin zeta for the treatment of anemia associated with chronic kidney disease. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A304.
Lee S, Lang K, Jackel J, Crivera C, Dirani R, Menzin J. Predictors of medication adherence among schizophrenia patients treated with conventional and atypical antipsychotics in a large state medicaid program. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada. [abstract] Value Health. 2008 May; 11(3):A123.
Graham JB, Earnshaw SR, Castelli-Haley J, Oleen-Burkey M, Johnson KP. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A381.
Leeuwenkamp O, Morlock R, Bell C, Brogan AJ, Mauskopf J. Costs and outcomes of atypical antipsychotics for the treatment of acute schizophrenia. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A301.
Marton J, Jackel J, Carson R, Rothermel C, Menzin J. Predictors of costs for skin and skin structure infections due to staphylococcus aureus using a managed-care perspective. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 2007. Dublin, Ireland. [abstract] Value Health. 2007 Nov; 10(6):A446.
Mauskopf JA, Brogan AJ, Malmberg C, Hwang P. A Canadian cost-effectiveness analysis of darunavir for HIV infection in treatment-experienced adults. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 2007. Arlington, VA. [abstract] Value Health. 2007 May; 10(3):A163.
Candrilli S, Davis KL, Mitra D, Tortella BJ, Joshi AV. Inpatient costs and outcomes associated with traumatic injury in the United States by injury severity and trauma center designation. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(3):A97.
Mitra D, Davis KL, Baran R. Health care utilization and costs associated with constipation (C-ONLY) and co-occurring irritable bowel syndrome and constipation (IBS+C) compared to migraine in a large managed care population. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(3):A148-9.
Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.
Javitt JC, Wolowacz SE, Roskell NS, Maciver F, Kelly S, Pleil AM, Zlateva GP. Cost-effectiveness of pegaptanib in age-related macular degeneration: the impact of differences between USA and UK health care systems. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Wolowacz SE, Roskell NS, Maciver F, Kelly S. Cost-utility analysis for pegaptanib in age-related macular degeneration in the UK: the impact of demographic and disease characteristics. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Candrilli S, Mauskopf J. How much does a day in the hospital cost? Value Health. 2006 May 1;9(3):A56.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson KP. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Value Health. 2006 May 1;9(3):A81-2.
McCrink L, Beard SM, Le T. The relationship between health-related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A41.
McCrink L, Beard S, Le TK. The relationship between health related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain (DPNP). Value Health. 2006 May 1;9(3):A41.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.